The DEA Is Dragging Its Feet on Cannabis Rescheduling — Here's Why It Matters
Advertisement
So here's the thing: we got an executive order. Back in December 2025, Trump signed one directing the Attorney General to complete cannabis rescheduling [Quick Definition: The federal process of moving cannabis from Schedule I to a less restrictive category] to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] "in the most expeditious manner possible." Sounds straightforward, right? Get it done fast.
Move weed from Schedule I to Schedule III. Done deal.
Except... it's not happening. Not yet, anyway. And honestly?
It's getting weird out there.
Table of Contents
- The Executive Order That Isn't Moving Mountains
- When Everything Got... Complicated
- The Status Report That Says "We're Still Waiting"
- What the Experts Are Actually Saying
- Why This Matters More Than You Might Think
- The Multiple Scenarios We're Looking At
- The Real Issue Nobody's Talking About Enough
- What Happens Now?
The Executive Order That Isn't Moving Mountains
Let's back up. If you've been following cannabis policy, you know this rescheduling thing has been the white whale of the industry for years. Schedule III would be huge—it would acknowledge that cannabis has legitimate medical uses, reduce the stigma, and open doors for research, banking, and interstate commerce.
It's not full legalization, but it's a massive shift.
The executive order seemed like the breakthrough moment. Finally, someone at the top saying "make this happen, and make it fast." The DEA got the memo in December. By January, there was supposed to be a public hearing where everyone could weigh in on the proposal.
January 21, 2025 was the scheduled date. The DEA would hear arguments from pro-rescheduling and anti-rescheduling parties. Public comment.
The whole administrative process. And then they'd move forward with a final rule.
That hearing was supposed to happen. It didn't.
When Everything Got... Complicated
Instead of proceeding, something strange happened: an administrative law judge (ALJ) granted an interlocutory appeal, canceled the hearing, and suspended the entire proceeding. If you're not fluent in government-speak, that basically means someone hit the emergency brake on the whole operation.
The appeal was filed by parties who opposed rescheduling. Their argument? The DEA has shown bias and has been giving preferential treatment to anti-rescheduling parties while blocking pro-rescheduling voices.
In other words, they're saying the agency that's supposed to be neutral is actually working against the proposal.
And here's where it gets really interesting: the pro-rescheduling party countered that the DEA was literally using "its authority in these proceedings to subvert the process and thwart the Schedule III proposal, which it vehemently opposes." Translation: the DEA doesn't want to reschedule cannabis and is using procedural tricks to kill the deal.
Think about that for a second. The DEA is the agency that's supposed to objectively evaluate the science and follow the legal process. But multiple parties are saying the institution itself is biased against rescheduling.
That's not just bureaucratic drama—that's a potential breakdown in how this process is supposed to work.
The Status Report That Says "We're Still Waiting"
Fast forward to the latest update. A joint status report filed with the administrative court says the rescheduling appeal "remains pending." No briefing schedule has been set. There's no timeline.
It's just... hanging there.
Meanwhile, the Congressional Research Service updated its report on cannabis policy. Want to know what they removed? Language saying it's "likely" that officials will move marijuana to Schedule III.
They took that out. That's not a small edit—it's an acknowledgment that the path forward is much murkier than it seemed a few months ago.
What the Experts Are Actually Saying
Legal firms tracking this closely, like Ropes & Gray, have been pretty blunt: significant hurdles remain. Even with the executive order, the DEA still has to follow the required administrative steps. The law doesn't let them just snap their fingers and reschedule something.
There's a process. And right now, that process is basically stuck.
The Cannabis Business Times ran an opinion piece with a headline that basically said what everyone's thinking: "not happening any time soon."
Why This Matters More Than You Might Think
So why should you care if the DEA is dragging its feet on a federal scheduling change? A few reasons:
Research access. If cannabis is Schedule I, it's nearly impossible to conduct federally-funded medical research. Researchers can't study what the schedule says doesn't have medical value. But if it moves to Schedule III, the research floodgates open.
That's how we figure out what actually works and what doesn't.
Industry legitimacy. Right now, cannabis businesses operate in this weird legal gray area. Banking is nearly impossible. Investor confidence is shaky.
Schedule III wouldn't solve everything, but it would be a massive step toward treating cannabis like a legitimate industry instead of a criminal enterprise.
Veteran and patient access. Medical professionals still can't prescribe cannabis, even though their patients are using it. The VA can't recommend it. Hospitals can't research it.
Schedule III opens those doors.
State-federal coordination. As long as cannabis is Schedule I federally, there's this constant tension with states that have legalized it. A rescheduling wouldn't fix everything, but it would reduce the contradiction at the heart of current drug policy.
The Multiple Scenarios We're Looking At
Here's what could happen next:
Scenario 1: The appeal gets resolved quickly. The court rules in favor of rescheduling, the DEA moves forward, and we get a final rule sometime in 2026. This is the optimistic path. It requires the court to side with pro-rescheduling parties and the DEA to actually cooperate.
Scenario 2: The appeal drags on. Litigation delays push the final rule into 2027 or beyond. The DEA files for extensions. More appeals get filed.
The process gets longer and messier. Given the current status, this seems increasingly likely.
Scenario 3: Something gives in the courts. One of the parties sues the DEA for bias or procedural violations. The whole thing gets tangled in litigation and the rescheduling process gets even more bogged down.
The Real Issue Nobody's Talking About Enough
Look, here's what's frustrating: the executive order exists. The legal authority to reschedule exists. The scientific evidence supporting medicinal uses exists.
But there's this institutional resistance from the DEA itself that's mucking up the works.
The agency has been anti-cannabis for decades. It's built its identity around drug enforcement. Rescheduling cannabis to Schedule III means admitting that the DEA's previous position—that marijuana has no medical value and is a serious threat—was wrong.
That's a hard pill to swallow for an institution, even when the evidence is overwhelming.
So instead of just getting it done, we're seeing what looks like institutional foot-dragging. Procedural delays. Appeals.
Bias claims. It's the bureaucracy equivalent of "I didn't hear you" while actively not listening.
What Happens Now?
The honest answer is nobody knows exactly. The appeal is pending. There's no briefing schedule.
The DEA isn't moving fast. The executive order is still technically in effect, but the "expeditious manner" part seems to be getting a very loose interpretation.
If you're in the cannabis industry, you're probably tired of waiting. If you're a researcher wanting to study cannabis, you're frustrated. If you're a patient who wants legitimate access, you're stuck.
The good news? The momentum toward rescheduling is real. It's not going away.
Even with the delays, the direction of travel is clear. More states are legalizing. More research is coming out.
More pressure is building. The DEA can delay, but it probably can't derail this completely.
The bad news? Don't expect this to wrap up in the next few months. We might be in the rescheduling limbo for the rest of 2026 and beyond.
Welcome to cannabis policy in 2026: where executive orders exist, but bureaucracy moves at its own glacial pace.
Pull-Quote Suggestions:
"The executive order seemed like the breakthrough moment."
"Schedule III would be huge—it would acknowledge that cannabis has legitimate medical uses, reduce the stigma, and open doors for research, banking, and interstate commerce."
"So here's the thing: we got an executive order."
Why It Matters: Despite Trump's executive order, cannabis rescheduling to Schedule III remains in limbo. Here is why the DEA is stalling and what it means for the industry.